Thymosin‐β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma

Retinoids are an important component of neuroblastoma therapy at the stage of minimal residual disease, yet 40–50% of patients treated with 13‐cis‐retinoic acid (13‐cis‐RA) still relapse, indicating the need for more effective retinoid therapy. Vorinostat, or Suberoylanilide hydroxamic acid (SAHA),...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Oncol
Autores principales: Cheung, Belamy B., Tan, Owen, Koach, Jessica, Liu, Bing, Shum, Michael S.Y., Carter, Daniel R., Sutton, Selina, Po'uha, Sela T., Chesler, Louis, Haber, Michelle, Norris, Murray D., Kavallaris, Maria, Liu, Tao, O'Neill, Geraldine M., Marshall, Glenn M.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2015
Materias:
Research Papers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528804/
https://ncbi.nlm.nih.gov/pubmed/25963741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.04.005
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares